Evidence map›Paper›PMID 20216555›Full record

Trial reportEuropean journal of clinical nutrition2010

Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial.

Y Kadooka, M Sato, K Imaizumi, A Ogawa, K Ikuyama, Y Akai, M Okano, M Kagoshima, T Tsuchida

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of clinical nutrition, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02539836 (Study on Dietary Nutrition Intervention Techniques for Children Obesity), which is not on this map. Cited by 278 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
278citing papers in PubMed, 10 pooled it
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02539836 nacompletednot on this mapstarted 2015, after this paper: background citation

Study on Dietary Nutrition Intervention Techniques for Children Obesity

TypeinterventionalSponsorChinese Academy of SciencesRan2015 to 2018Enrolled90ConditionsObesity, Intestinal Bacteria Flora Disturbance, Body WeightArmsDietary nutrition based on plant fermentation extract, MRI in quantifying liver fat with MRS
3 · Its place in the literature

Who cites it

278 citing papers in PubMed, 10 syntheses or guidelines pooled it, 682 citations in OpenAlex.

  1. Pooled it
  2. ProbioticNarra J · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Effects ofNutrients · 2024
    Trial
  16. Trial
  17. Nutrients · 2023
    Trial
  18. Trial
  19. Safety and Effects ofNutrients · 2023
    Trial
  20. Trial

218 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Y KadookaTechnology and Research Institute, Snow Brand Milk Products Co. Ltd., Kawagoe, Saitama, Japan. y-kadooka@snowbrand.co.jp
M Sato
K Imaizumi
A Ogawa
K Ikuyama
Y Akai
M Okano
M Kagoshima
T Tsuchida
Kyushu University · JPMegmilk Snow Brand (Japan) · JPIwaki Meisei University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesIn spite of the much evidence for the beneficial effects of probiotics, their anti-obesity effects have not been well examined. We evaluated the effects of the probiotic Lactobacillus gasseri SBT2055 (LG2055) on abdominal adiposity, body weight and other body measures in adults with obese tendencies. SUBJECTS/

methodsWe conducted a multicenter, double-blind, randomized, placebo-controlled intervention trial. Subjects (n=87) with higher body mass index (BMI) (24.2-30.7 kg/m(2)) and abdominal visceral fat area (81.2-178.5 cm(2)) were randomly assigned to receive either fermented milk (FM) containing LG2055 (active FM; n=43) or FM without LG2055 (control FM; n=44), and were asked to consume 200 g/day of FM for 12 weeks. Abdominal fat area was determined by computed tomography.

resultsIn the active FM group, abdominal visceral and subcutaneous fat areas significantly (P<0.01) decreased from baseline by an average of 4.6% (mean (confidence interval): -5.8 (-10.0, -1.7) cm(2)) and 3.3% (-7.4 (-11.6, -3.1) cm(2)), respectively. Body weight and other measures also decreased significantly (P<0.001) as follows: body weight, 1.4% (-1.1 (-1.5, -0.7) kg); BMI, 1.5% (-0.4 (-0.5, -0.2) kg/m(2)); waist, 1.8% (-1.7 (-2.1, -1.4) cm); hip, 1.5% (-1.5 (-1.8, -1.1) cm). In the control group, by contrast, none of these parameters decreased significantly. High-molecular weight adiponectin in serum increased significantly (P<0.01) in the active and control groups by 12.7% (0.17 (0.07, 0.26) microg/ml) and 13.6% (0.23 (0.07, 0.38) microg/ml), respectively.

conclusionThe probiotic LG2055 showed lowering effects on abdominal adiposity, body weight and other measures, suggesting its beneficial influence on metabolic disorders.

Indexed as

Body WeightLactobacillusAbdominal FatAdiponectinAdultBody Mass IndexDouble-Blind MethodFemaleHipHumansIntra-Abdominal FatMaleMiddle AgedObesityObesity, AbdominalProbioticsAdiponectin

Identifiers

PMID20216555
OpenAlexW2069973024

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.